 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| ARCT-165 / Arcturus Therap, Kostaive (ARCT-154) / Arcturus Therap, ARCT-021 / Arcturus Therap, CSL Behring, Meiji Seika
Trial completion, Trial completion date, Trial primary completion date: A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults (clinicaltrials.gov) - Jul 30, 2024
P1/2, N=72, Completed, Sponsor: Arcturus Therapeutics, Inc.
Recruiting --> Completed | Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Mar 2023 --> Dec 2023
- Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, ARCT-165 / Arcturus Therap, ARCT-154 / Arcturus Therap
Vaccination of non-human primates with self-amplifying mRNA vaccines reveal two distinct immunotypes across major SARS-CoV-2 variants. (Exhibit Hall; P1055) - Apr 8, 2022 - Abstract #IMMUNOLOGY2022IMMUNOLOGY_2015;
P1/2
However, in the context of a booster dose in humans (NCT05037097), ARCT-154 provides robust humoral responses across all variants tested. Next generation self-amplifying mRNA vaccines may provide better coverage and at booster doses that are 6-10 times lower than those of currently authorized mRNA vaccines.
- |||| ARCT-165 / Arcturus Therap, Kostaive (ARCT-154) / Arcturus Therap, ARCT-021 / Arcturus Therap, CSL Behring, Meiji Seika
New P1/2 trial: A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults (clinicaltrials.gov) - Sep 7, 2021
P1/2, N=72, Recruiting, Sponsor: Arcturus Therapeutics, Inc.